Cambridge Cognition, Takeda team up for depressive-disorder study
Shares in Cambridge Cognition rose more than 9% on news it has teamed with Japanese pharmaceutical Takeda to pilot the use of an Apple Watch app to monitor and assess cognitive function in patients with major depressive disorder.
Cambridge Cognition Holdings
37.50p
16:55 03/01/25
FTSE AIM All-Share
725.40
17:15 03/01/25
Health Care Equipment & Services
10,644.60
16:54 03/01/25
The collaboration is the first contract signed by Cognition Kit Ltd, the joint venture with Ctrl Group, since launching the wearable cognitive technology in 2016.
The AIM-listed digital health company claimed that there had been “significant” interest already from a number of commercial partners.
Major depressive disorder affects about 350m people of all ages worldwide and cognitive problems are common in major depression, and may be under-recognised by patients and clinicians.
The Cognition Kit app is designed to gauge symptoms, advancing patient assessment and monitoring outside of the lab into everyday life to help maximise patient engagement.
The study will involve 30 participants aged 18-65 with a clinical diagnosis of mild-to-moderate depression, and who have been prescribed an antidepressant for major depressive disorder.
It will evaluate the feasibility and compliance of the wearable technology. It will also aim to see how measures of mood and cognition on wearable technology compare to more traditional neuropsychological testing and patient reported assessments.
The results of the are expected in first-half 2017.
At 10:46 GMT, shares in Atlantis Resources were up 9.6% to 55.35p each.